SOCIOMICS
LIVE

Serial Number

97356365

Owner

Phenomics Health Inc.

Attorney

Roger H. Bora

Filing Date

Apr 11, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SOCIOMICS Trademark

Serial Number: 97356365

SOCIOMICS is a trademark filed by Phenomics Health Inc. on April 11, 2022. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Phenomics Health Inc. (11 trademarks)

60 Yorkshire Drive
Hilton Head Island, SC 29928

Entity Type: 03

Trademark Details

Filing Date

April 11, 2022

Registration Date

Not Registered

Published for Opposition

March 21, 2023

Goods & Services

Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, and the data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching; scientific and technological services in the field of pharmaceuticals featuring pharmacogenomic testing, analysis, and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of analyzing how an individual's cultural and environmental factors affect their response to drugs, and for the purposes of improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs switching; scientific and technological services, namely, scientific testing, evaluation, and analysis in the field of pharmaceuticals to determine a patient's medication and drug response associated with environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services, namely, scientific testing, evaluation, and analysis in the field of pharmaceuticals to determine a patient's medication and drug response associated with environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors, together with genetic variants, epigenetic factors and multiomics to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of supporting drug clinical trials and research into the field of new drug development and drug repurposing; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions, including stress resulting from adverse conditions, age-related health, isolation or cognitive circumstances, behavior harmful to self or others, childhood and adolescent neglect and abuse, adult trauma associated with events, including sexual, physical and psychological abuse, acute or chronic traumatic events, including military conflict, crimes, crashes, illnesses and family deaths, stress, trauma, abuse, poverty, food insecurity and hunger, imprisonment, interpersonal conflict, violence, presence or absence of parents, children, siblings, and other family members and acquaintances, gender, ancestry, transgenerational social factors, age, income, marital status, education level, language, other household data, cultural situations, circadian data, ethnicity-related health, community living conditions, biological sex, ethnicity, and other non-genetic factors; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation to determine a patient's medication and drug response associated with cultural and environmental factors, including stress resulting from adverse conditions, age-related health, isolation or cognitive circumstances, behavior harmful to self or others, childhood and adolescent neglect and abuse, adult trauma associated with events, including sexual, physical and psychological abuse, acute or chronic traumatic events, including military conflict, crimes, crashes, illnesses and family deaths, stress, trauma, abuse, poverty, food insecurity and hunger, imprisonment, interpersonal conflict, violence, presence or absence of parents, children, siblings, and other family members and acquaintances, gender, ancestry, transgenerational social factors, age, income, marital status, education level, language, other household data, cultural situations, circadian data, ethnicity-related health, community living conditions, biological sex, ethnicity, and other non-genetic factors; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's periodic changes in response to medical treatment, pharmacological adverse reactions, drug-drug interactions, drug dosing changes, and new or recurring comorbidities

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 2, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jan 2, 2025 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 2, 2025 AITU
SOU EXTENSION 3 FILED
Nov 14, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 18, 2024 EXRA
SOU EXTENSION 2 GRANTED
Apr 18, 2024 EX2G
SOU EXTENSION 2 FILED
Apr 18, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 18, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 1, 2023 EXRA
SOU EXTENSION 1 GRANTED
Oct 30, 2023 EX1G
SOU EXTENSION 1 FILED
Oct 30, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 30, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 16, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 10, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 9, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 9, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 11, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 11, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 11, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 15, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 15, 2022 NWOS
NEW APPLICATION ENTERED
Apr 14, 2022 NWAP